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Virus-Encoded Homologs of Cellular Interleukin-10 and Their Control
of Host Immune Function
Barry Slobedman,1#* Peter A. Barry,2# Juliet V. Spencer,3#
Selmir Avdic,1# and Allison Abendroth4#
Centre for Virus Research, Westmead Millennium Institute and University of Sydney, Sydney, Australia1; Center for
Comparative Medicine, University of California, Davis, California2; Department of Biology, University of
San Francisco, San Francisco, California3; and Department of Infectious Diseases and Immunology,
University of Sydney, Sydney, Australia4
The capacity of viruses to successfully infect the immuno-
competent host to cause disease argues in favor of virus-en-
coded functions that specifically target components of the im-
mune system so as to orchestrate an environment that limits
the capacity of the host immune response to clear infection. In
this respect, many viruses have evolved to coexist with the host
immune system by developing an arsenal of strategies to avoid
immune surveillance and elimination from the host. These
include viruses which have acquired homologs of cellular cy-
tokines or cytokine receptors as a strategy to limit host immune
recognition. Cellular interleukin-10 (IL-10) is a pleiotropic
immunomodulatory cytokine produced by a wide variety of
cells, including monocytes, macrophages, T and B lympho-
cytes, dendritic cells (DC), keratinocytes, epithelial cells, and
mast cells. The properties of IL-10 have been comprehensively
reviewed elsewhere (12, 69, 70, 72, 77) and so will not be
covered in detail here, but the key features of this cytokine
relate mainly to its capacity to exert potent immunosuppressive
functions on the expression of a range of cytokines and che-
mokines (2, 16, 23), as well as the repression of major histo-
compatibility complex (MHC) molecules and costimulatory
molecules (17, 104) and the maturation and function of DC
(69). The immunosuppressive properties of IL-10 are primarily
restricted to cells of the myeloid lineage (69). In contrast, IL-10
has been shown to exert a stimulatory effect on B lymphocytes
(15, 28, 87), mast cells (99), thymocytes (64), and CD8 T cells
(31, 88, 90), highlighting the cell-type-dependent immuno-
modulatory properties of this cytokine. The immunomodula-
tory functions manifested by IL-10 require engagement of this
cytokine with its cell surface bound receptor. The IL-10 recep-
tor (IL-10R) consists of two different subunits (IL-10R1 and
IL-10R2) (52, 60). IL-10 binds first to IL-10R1 with high af-
finity, and the resulting intermediate IL-10/IL-10R1 complex
then binds with lower affinity to IL-10R2. The resulting active
signaling complex induces the JAK/Stat signal transduction
pathway (69, 72). In the context of viral pathogenesis, infec-
tions with a number of different viruses have been documented
to upregulate the expression of IL-10, and in some cases, this
upregulation has been shown to enhance infection by suppress-
ing the immune function, suggesting that the far-reaching ef-
fects of this cytokine have many advantages for invading patho-
gens (3, 4, 18, 30, 45, 81, 82, 108, 111).
IL-10-like open reading frames (ORF) have been identified
by sequence homology in multiple members of the Herpesvi-
rales and Poxviridae, all but one of which infect mammalian
hosts (Table 1). The one exception, cyprinid herpesvirus 3, is a
member of the Alloherpesviridae family of herpesviruses (order,
Herpesvirales), which has the common carp (Cyprinus carpio) as
its normal host (1). Otherwise, all of the herpesviruses identi-
fied to date as encoding IL-10-like ORF, including human
cytomegalovirus (HCMV) and Epstein-Barr virus (EBV), are
found only in the Beta- and Gammaherpesvirinae subfamilies of
the Herpesviridae. No examples of the Alphaherpesvirinae that
encode IL-10 homologs have been identified. Of the identified
members of the Herpesviridae that encode IL-10 homologs, all
but two, equid herpesvirus 2 and ovine herpesvirus 2 (OvHV2)
(85, 96, 97), are confined to primate hosts (Table 1). All of the
identified Poxviridae that encode IL-10 infect ruminants, in-
cluding orf virus ([ORFV] sheep and goats), sheeppox virus
([SPPV] sheep), goatpox virus ([GPV] goats), and lumpy skin
disease virus ([LSDV] cattle). The genomes of SPPV, GPV,
and LSDV are 96 to 97% identical at the nucleic acid level (48,
101). Another member of the Poxviridae that has monkeys as
its normal host, yaba-like disease virus, encodes an ORF
(Y134R) that exhibits sequence homology to the IL-10-related
cytokines IL-19, IL-20, and IL-24 (57). These viral IL-10 (vIL-
10) homologs range in size from 139 to 191 amino acids (aa),
bracketing the range in sizes for cellular IL-10 proteins (176 to
180 aa).
The role of virus-encoded IL-10 homologs is likely to pro-
vide a tool to enable modulation of the local immune response
so as to enhance the capacity to replicate, disseminate, and/or
persist in an otherwise immunocompetent individual. In fact,
there is emerging evidence that virus-encoded IL-10 homologs
function in this capacity in a variety of settings. This review will
cover those viruses which have thus far been identified as
encoding homologs of IL-10. The similarities of each homolog
to the IL-10 of the natural host species will be presented
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together with their biological functions (where known) and the
role they may play in viral pathogenesis and evasion of the host
immune response.
EBV
EBV-encoded BCRF1, the first vIL-10 homolog described,
was identified shortly after the discovery of the cellular cyto-
kine. IL-10 was initially known as CSIF, or cytokine synthesis
inhibitory factor, an activity produced by murine TH2 cells that
inhibited cytokine production by TH1 cells (22). When the
mouse and human cDNAs for CSIF/IL-10 were sequenced, the
protein products were found to have 70% amino acid sequence
identity with an uncharacterized ORF of EBV, BCRF1 (71).
BCRF1 refers to BamHI-C fragment rightward reading frame
1, and when the BCRF1 gene was cloned and expressed, the
resulting 17-kDa protein inhibited synthesis of gamma inter-
feron (IFN-) from a stimulated mouse TH1 clone and from
human peripheral blood mononuclear cells (PBMC) (35).
Cytokine production was inhibited by BCRF1 regardless of
whether PBMC were stimulated with phytohemagglutinin, IL-12,
or anti-CD3 antibodies, suggesting that EBV IL-10 (ebvIL-10)
could act on multiple cell types and inhibit cytokine synthesis by
both T cells and NK cells (35).
In parallel, numerous studies were conducted to document
the biological activities of both human IL-10 (hIL-10) and
ebvIL-10. Both cytokines were found to have broad immuno-
suppressive properties, including inhibition of inflammatory
cytokine production (16, 35, 36, 103), deactivation of macro-
phages (73, 74), and inhibition of T-cell proliferation via re-
duction of MHC class II molecules on the surfaces of mono-
cytes (17). Immunostimulatory functions were also noted; both
hIL-10 and ebvIL-10 promoted proliferation and differentia-
tion of B cells, as well as stimulating immunoglobulin produc-
tion (15, 28, 87). However, it soon became apparent that the
viral cytokine had not retained all properties of cellular IL-10.
While human and murine IL-10 costimulated mouse thymo-
cyte proliferation and mast cell proliferation and promoted
upregulation of MHC class II surface expression on B cells,
ebvIL-10 lacked these functions (28, 64, 103). Further exami-
nation also revealed that the ability to inhibit IL-2 production
by a CD4 T-cell clone was greatly reduced in comparison with
that of the cellular IL-10s and that ebvIL-10 had an approxi-
mately 1,000-fold-lower affinity for the cellular IL-10R than did
hIL-10 (59).
Since the viral gene was most likely captured from the host
and evolved over time to retain properties that were most
beneficial in promoting virus persistence, these differences in
biologic activity were not completely unexpected. Examination
of the primary amino acid sequence and the crystal structure
suggested possible reasons for these functional differences. In
the primary sequence, an isoleucine at position 87 of murine
and PhIL-10 was found to be essential for stimulatory activity
on thymocytes, mast cells, and alloantigenic responses (19).
Substitution of an alanine at this position in hIL-10 resulted in
loss of stimulatory activities, while immunosuppressive func-
tions were not affected. The wild-type ebvIL-10 protein nor-
mally contains an alanine at this position, and when a mutation
substituting isoleucine for the alanine was made, the viral cy-
tokine gained the ability to stimulate proliferation of MC/9
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cells, although the proliferation was not as robust as that ob-
served with wild-type hIL-10 (19). These results demonstrate
that even a single amino acid can impact a cytokine’s func-
tional repertoire.
With the exception of the N-terminal 20 amino acids (the
signal peptide), the human and ebvIL-10 sequences are highly
conserved (35). Determination of the crystal structure demon-
strated that like hIL-10, ebvIL-10 forms a homodimer consist-
ing of two domains (113). Each monomer contains six helices,
with four helices in one domain and two in the other, with the
two monomers connected, forming an axis of twofold symme-
try. Subtle changes in two loop structures and the resulting
change in orientation of the ebvIL-10 dimer to the cellular
IL-10R are believed to be responsible for the decreased bind-
ing affinity and limited functionality of the viral cytokine (110)
(Fig. 1).
Because ebvIL-10 lacks several immunostimulatory func-
tions of the cellular cytokine, there has been great interest in
investigating the therapeutic potential of the viral cytokine,
particularly for autoimmune diseases or conditions associated
with chronic inflammation. In animal models, ebvIL-10 was
found to be effective in inhibiting collagen-induced arthritis
(49, 50, 63), suppressing autoimmune diabetes (109), amelio-
rating symptoms of necrotizing pancreatitis (67), and improv-
ing survival of sepsis (75). In particular, ebvIL-10 has distinct
advantages over hIL-10 in transplantation models, and the
viral cytokine has consistently enhanced graft acceptance and
survival in various models (10, 51, 69, 78, 89).
Exploitation of IL-10 is a common theme among intracellu-
lar pathogens (82), as the immunosuppressive properties of the
cytokine may facilitate escape from immune detection. How-
ever, for EBV, it is not entirely clear whether the target of
ebvIL-10 is mainly antigen-presenting cells to enable addi-
tional time for the virus to establish latency, or whether effects
on B cells are necessary for transformation. Although BCRF1
was initially characterized as a late gene (37), other reports
suggest that it is expressed within 6 to 9 h of infection (68, 100)
and show an essential role for ebvIL-10 in B-cell transforma-
tion (39, 68). Regardless, the ability of this viral cytokine to
promote B-cell proliferation and differentiation would most
likely increase the number of latently infected cells in circula-
tion in the host.
HCMV
vIL-10 EXPRESSION DURING PRODUCTIVE
HCMV INFECTION
The first identification of a homolog of IL-10 expressed by
HCMV was reported almost simultaneously by two separate
groups in 2000. The Barry and Pestka groups isolated cDNA
from the HCMV UL111A region in productively infected
MRC-5 and HEL 299 cells, respectively (54, 61). Further char-
acterization revealed the presence of a transcript (denoted
cmvIL-10) generated from three exons and two introns that
was predicted to encode a protein of 175 aa with homology to
hIL-10. The cmvIL-10 protein contains a signal peptide, and
studies of cells transfected with cDNA expression constructs or
productively infected with HCMV confirmed that cmvIL-10
protein is secreted into culture supernatants (8, 43, 54, 94). In
addition, a putative N-linked glycosylation site was identified at
Asn-151-X-Thr-153 (54), and Western blot analyses supported
the presence of both nonglycosylated (21 kDa) and larger
glycosylated forms of cmvIL-10 (8, 43, 54, 58, 94).
Based upon comparison of amino acid sequence, cmvIL-10
shares only 27% identity with hIL-10, in contrast to ebvIL-10,
which is 80% identical (54, 61, 71). Despite this low homol-
ogy to hIL-10, cmvIL-10 can bind to the hIL-10R (47, 54). The
crystal structure of cmvIL-10 bound to the extracellular frag-
ment of the ligand binding subunit (IL-10R1) of hIL-10R has
been resolved (47). Like hIL-10, cmvIL-10 forms a homodimer
that binds two hIL-10R1 subunits, although analysis of this
interaction has revealed some differences between cmvIL-10
and hIL-10. In contrast to that of hIL-10, the cmvIL-10
homodimer is linked via a disulfide bond formed between
the two cysteine residues on corresponding protein mole-
FIG. 1. Structure of hIL-10 and vIL-10 homologs bound to the
hIL-10R. hIL-10 (A), ebvIL-10 (B), and cmvIL-10 (C) dimers bound to
soluble IL-10R1 (sIL-10R1) are shown. The interdomain angles of
each IL-10 are shown at the top of each complex. The rotation (in
degrees) of each IL-10 domain angle on the surface of sIL-10R1 is
denoted by arrows where the movement is from the circle to the
arrowhead. For the cmvIL-10/sIL-10R1 complex, the rotation of each
sIL-10R1 relative to the hIL-10/sIL-10R1 complex is also shown.
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cules (position 59 in cleaved proteins or position 78 in pro-
teins with the signal peptide still attached). The interdomain
angle of cmvIL-10 is 130° (compared to 89° in hIL-10),
resulting in reorganization of IL-10R1 when bound to the
cmvIL-10 homodimer compared to the hIL-10/IL-10R1 com-
plex (47, 110) (Fig. 1). Importantly, though, despite the low
amino acid homology and the difference in the interdomain
angles of cmvIL-10 and hIL-10 homodimers, cmvIL-10 binds
strongly to IL-10R1, with a slightly greater affinity than even
hIL-10 and a much greater affinity than ebvIL-10 (47, 59).
While cmvIL-10 efficiently binds to hIL-10R1, two common
variants of this receptor, each containing single-nucleotide
polymorphisms, were less susceptible to cmvIL-10-induced sig-
naling (32). IL-10R1 variants may therefore affect the capacity
of HCMV to escape from the host immune response, although
studies to evaluate the effect of IL-10R1 variants on the clinical
course of HCMV infection of different individuals will be re-
quired to test this hypothesis. Due to the larger interdomain
angle and slightly different rotation of the cmvIL-10 dimer, the
cmvIL-10/IL-10R1 complex changes its orientation, which af-
fects the IL-10R2 binding site. As a result, the cmvIL-10/IL-
10R1 complex shows greater affinity for soluble IL-10R2 and
binds 3 to 5 times as much IL-10R2 as the hIL-10/IL-10R1 and
ebvIL-10/IL-10R1 complexes (110).
The possibility that differences in these structural changes
unique to cmvIL-10 may alter the range of biological proper-
ties encoded by cmvIL-10 has been previously raised (47), and
this does appear to be the case for at least one other vIL-10
homolog, as ebvIL-10 is unable to stimulate thymocyte or mast
cell proliferation or B-cell MHC class II expression, whereas
hIL-10 can (28, 64, 103). To date, however, the repertoire of
immunomodulatory properties of hIL-10 has been shown to
also be exerted by cmvIL-10. These include both immunosup-
pressive and immunostimulatory functions which are mani-
fested in a cell-type-dependent manner.
PBMC proliferation and production of proinflammatory
cytokines IL-1, IL-6, granulocyte-macrophage colony-stim-
ulating factor, and tumor necrosis factor alpha (TNF-) in
lipopolysaccharide (LPS)-treated PMBC and monocytes is
inhibited by recombinant cmvIL-10 protein or the supernatant
from cells transfected with a cmvIL-10 expression construct
(94). In the same study, these treatments were also reported to
decrease MHC class I and MHC class II expression by mono-
cytes but increase the nonclassical MHC class I molecule
HLA-G, which can confer protection from natural killer cell-
mediated lysis of MHC class I-negative cells (86). The link
between the binding of cmvIL-10 to the hIL-10R and the
functional properties of cmvIL-10 was provided by experi-
ments utilizing antibodies that block the hIL-10R. Neutralizing
antibody to the hIL-10R blocks the capacity of recombinant
cmvIL-10 to either inhibit PBMC proliferation or downregu-
late MHC class II by monocytes (44, 94). This vIL-10 homolog
has also been shown to upregulate the expression of Fc re-
ceptors and stimulate phagocytosis of immunoglobulin G-op-
sonized erythrocytes by human monocytes, with one interpre-
tation of these results being that cmvIL-10 skews monocyte
differentiation toward a more phagocytic phenotype and away
from an antigen presentation phenotype (40).
The signaling pathway utilized by cmvIL-10 in monocytes
appears to be similar to that used by hIL-10, where the classic
IL-10R/JAK1/Stat3 pathway was found to be triggered by both
cmvIL-10 and hIL-10 (92). Phosphorylation of Stat3 (but not
Stat1) was readily detectable in monocytes treated with
cmvIL-10 and hIL-10, but Stat3 phosphorylation was pre-
vented in the presence of the JAK1 inhibitor, indicating that
binding of cmvIL-10 to the IL-10R leads to JAK1-dependent
Stat3 activation. Surprisingly, the JAK1/Stat3 pathway did not
appear to play a significant role in the control of TNF- sup-
pression by cmvIL-10 in LPS-induced monocytes. No signifi-
cant increase in TNF- levels was observed when monocytes
were preincubated with the JAK1 inhibitor, indicating that the
JAK1/Stat3 pathway may not be the only signaling pathway
utilized in inhibiting cytokine synthesis in monocytes. Indeed,
further investigation demonstrated that Stat3 phosphorylation
was also achieved by interaction with phosphoinositide 3-ki-
nase (PI3K), but phosphorylation occurred at a different posi-
tion in the Stat3 sequence, where S727 was phosphorylated by
PI3K, whereas Y705 was phosphorylated by JAK1 (92). TNF-
expression was somewhat restored by the addition of PI3K
inhibitors, indicating that PI3K-mediated Stat3 phosphoryla-
tion plays a role in the induction of proinflammatory cytokine
inhibition by cmvIL-10 in monocytes. However, the reversal of
TNF- inhibition by the blockage of PI3K was only partial,
thus indicating that cmvIL-10 may use other IL-10R-signaling
pathways or even utilize other receptors to accomplish immu-
nosuppression of proinflammatory cytokines.
While the study by Spencer et al. (94) reported reduced
MHC class I surface expression on LPS-stimulated human
monocytes exposed to recombinant cmvIL-10, Pepperl-Klind-
worth et al. (76) did not observe a function for cmvIL-10 in the
context of virus infection and its impact on MHC class I-re-
stricted antigen presentation by bystander (uninfected) cells.
Incubation of the myeloid progenitor cell line THP-1 with
recombinant cmvIL-10 protein combined with the superna-
tants from human fibroblasts productively infected with a cm-
vIL-10 deletion virus did not impair MHC class I-restricted
antigen presentation by the THP-1 cells. In addition, there was
no difference in MHC class I-restricted antigen presentation by
an EBV-transformed B-cell line, JY-LCL, when these cells
were coincubated with fibroblasts productively infected with
either parental or vIL-10 deletion viruses. These experiments
suggest that in the context of productive HCMV infection,
cmvIL-10 does not impair MHC class I-restricted antigen pre-
sentation by uninfected bystander cells, the implication being
that the milieu of cytokines secreted by productively infected
cells affects the net immunomodulatory impact of secreted
cmvIL-10 on MHC class I function by bystander cells. Alter-
natively, the number of surface MHC class I molecules on
bystander cells may be reduced by cmvIL-10, but the number
remaining may still be sufficient for antigen presentation.
These possibilities remain to be explored, as does the deter-
mination of whether productive infection influences the capac-
ity of secreted cmvIL-10 to modulate MHC class I-restricted
function by primary monocytes and other myeloid cell types.
There is strong evidence that cmvIL-10 negatively affects DC
function. It has been shown that cmvIL-10 prevents LPS-in-
duced maturation and proinflammatory cytokine production of
immature DC treated with culture supernatants from HCMV-
infected cells but not culture supernatants from cells infected
with a cmvIL-10 deletion virus (8). In addition, although
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cmvIL-10 enhanced the migration of mature DC, it also greatly
suppressed their cytokine production. The prolonged effect of
cmvIL-10 on activated DC was demonstrated by IL-12 produc-
tion which could not be reestablished even after DC restimu-
lation with the CD40 ligand in the absence of cmvIL-10 (8).
Raftery et al. (80) evaluated various effects of cmvIL-10 on
immature, LPS-induced, and mature DC, showing strong acti-
vation of a mediator of IL-10 response, Stat3, in immature DC
as well as upregulation of a lectin receptor, DC-SIGN, on
immature but not on mature cells. One of the reported func-
tions of DC-SIGN is as a coreceptor for HCMV entry (34),
raising the possibility that cmvIL-10 may also aid viral entry by
increasing DC-SIGN expression on immature DC, although
this function remains to be shown in any experimental setting.
This study also reported a partial blockage of MHC class I and
class II upregulation accompanied by an increase in expression
of the nonclassical MHC molecule HLA-DM. Upregulation of
the costimulatory molecules CD40, CD80, CD86, B7-DC, and
B7-H1 was also prevented by cmvIL-10 on LPS-stimulated DC,
and cmvIL-10 increased apoptosis associated with DC matu-
ration by blocking upregulation of antiapoptotic long-form cel-
lular FLIP. Continuing work from the same group demon-
strated that the number of transcripts, as well as cell surface
expression of the CD1 group of molecules (nonclassical major
MHC class I molecules), was also inhibited by cmvIL-10 in DC
(79). Together, these studies highlight a role for cmvIL-10 in
repressing a critical arm of the immune response by shaping
the phenotype of DC.
In addition, a recent study demonstrated that cmvIL-10, like
IL-10, can directly suppress synthesis of type I IFNs in plas-
macytoid DC, which represent, under normal circumstances,
the predominant source of type I IFNs (6). Plasmacytoid DC
are highly resistant to infection with HCMV, suggesting that
cmvIL-10 acts in trans to potently inhibit type I IFN produc-
tion. Since type I IFNs block infection of susceptible cells by
HCMV in a dose-dependent manner, the results further sug-
gest that secretion of cmvIL-10 by infected cells may facilitate
the systemic spread of HCMV during the earliest stages of
infection and attenuate the development of antiviral immune
responses.
The impact of cmvIL-10 has also been assessed on microglial
cells (resident macrophages exclusive to the brain) to shed
light on the potential subversion of neuroimmune responses
during HCMV encephalitis. Pretreatment of these cells with
recombinant cmvIL-10 protein prior to HCMV infection re-
sulted in a striking decrease in the protein levels of a potent
antiviral molecule, CXC chemokine ligand 10 (CXCL10), in
infected microglial cells. This chemokine is strongly induced
upon infection with HCMV, which leads to increased chemo-
taxis of activated T cells toward infected cells (9). The treat-
ment of microglial macrophages with conditioned media from
astrocytes productively infected with HCMV in the presence or
absence of anti-IL-10R neutralizing antibody showed a de-
crease of CXCL10 levels in samples where cellular IL-10Rs
were not blocked by this antibody, further highlighting a role of
cmvIL-10 in the control of CXCL10 expression by microglial
cells (9).
In the context of congenital infection, which remains one of
the most clinically significant aspects of HCMV infection,
Yamamoto-Tabata et al. (108) demonstrated that recombinant
cmvIL-10 increased hIL-10 expression by cytotrophoblasts and
decreased matrix metalloproteinase activity in endothelial cells
and cytotrophoblasts and impaired endothelial cell migration
in wound closure assays and cytotrophoblast invasiveness of
Matrigel. These are critical components required for proper
development of the placental-uterine interface, raising the pos-
sibility that cmvIL-10 expressed during HCMV infection of
pregnant women may impair cytotrophoblast remodeling of
the uterine vasculature and consequently limit fetal growth.
This finding provides stimulus for a more detailed analysis of
the role cmvIL-10 may play in congenital HCMV infection.
In an example of the potential to harness the immunosup-
pressive properties of cmvIL-10 for a therapeutic purpose, the
impact of cmvIL-10 on the foreign body reaction (FBR) to
implanted biomaterial has been assessed. The use of biomate-
rials such as temporary scaffolds for structural support to assist
in the delivery of cells or soluble mediators to repair damaged
organs is complicated by the host FBR, an inflammatory reac-
tion to degrade the foreign biomaterial. In this setting,
cmvIL-10 has been reported to impair the progression of the
FBR to hexamethylene diisocyanate-cross-linked dermal sheep
collagen discs loaded with recombinant cmvIL-10 and im-
planted into rats, suggesting that cmvIL-10 may be a useful
adjunct in biomaterials for regenerative medicine (102).
Apart from its immunomodulatory properties on myeloid
cells, cmvIL-10 has been shown to induce the growth and
differentiation of a human B-cell lymphoma Daudi cell line,
increasing the number of cells by 60% compared to the num-
ber of untreated cells (93). cmvIL-10 also increased the levels
of hIL-10 and, to a smaller extent, IL-10R produced by B cells
and did not alter surface MHC class II levels. Thus, like hIL-
10, cmvIL-10 can act in either an immunosuppressive or an
immunostimulatory capacity, depending on the cell type to
which it is exposed.
vIL-10 EXPRESSION DURING LATENT
HCMV INFECTION
HCMV confronts the challenge of latently infecting myeloid
cells that are themselves components of the immune system.
The capacity of HCMV to establish and maintain latency in
these cells in the face of a robust host immune system argues
for a dynamic interplay between virus and host, where HCMV
encodes immunomodulatory functions that ensure its survival
during this phase of infection. In both an experimental model
of latent infection utilizing primary human myeloid progenitor
cells and in mononuclear cells from healthy bone marrow and
mobilized peripheral blood donors, transcriptional activity
from the UL111A gene region has been detected by reverse
transcription-PCR (42). The transcript was designated latency
associated cmvIL-10 (LAcmvIL-10). The precise initiation site
of LAcmvIL-10 transcription was isolated to a 38-bp region
between nucleotides 159577 and 159615 (AD169 strain), as
opposed to the initiation site of cmvIL-10 transcription, which
has been mapped to nucleotide position 159642. Nonetheless,
the initiation of translation of both LAcmvIL-10 and cmvIL-10
is predicted to occur at the same methionine at nucleotide
position 159678, and the termination site of LAcmvIL-10 tran-
scription is shared with that of cmvIL-10 at nucleotide position
160430. The major difference between the LAcmvIL-10 tran-
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script and the cmvIL-10 transcript lies in differential splicing;
LAcmvIL-10 retains only the first of the two introns found in
cmvIL-10, resulting in an in-frame stop codon at nucleotide
position 160171 (AD169 strain). As a consequence, the
LAcmvIL-10 protein shares the first 127 amino acids with
cmvIL-10 but then diverges for its final 12 amino acids at the
C terminus, resulting in a truncated protein of 139 amino acids
(42). At the protein level, LAcmvIL-10 shares 27% identity
and 46% similarity with hIL-10.
The assessment of biological properties of LAcmvIL-10 has
thus far been carried out mainly using recombinant proteins
generated from either bacterial or mammalian cell expression
systems. LAcmvIL-10 reduces cell surface MHC class II ex-
pression by monocytes and more-primitive myeloid progenitor
cells in a manner comparable to that of cmvIL-10. Both LAc-
mvIL-10 and cmvIL-10 reduce the levels of transcription of
components of the MHC class II biosynthesis pathway, includ-
ing the HLA-DR chain, HLA-DR chain, and the invariant
chain. Transcription of the master regulator of MHC class II,
the class II transactivator (CIITA), which controls expression
of these MHC class II components, is also reduced by LAcm-
vIL-10 and cmvIL-10, pointing to a mechanism of MHC class
II downregulation at the level of the transcriptional activity of
CIITA (44). In the same study, MHC class II was also observed
to accumulate in punctate cytoplasmic vesicles in a small pro-
portion (3 to 5%) of monocytes treated with LAcmvIL-10 or
cmvIL-10, suggesting that in addition to control at the level of
transcription of CIITA, LAcmvIL-10 and cmvIL-10 may exert
a repressive effect on MHC class II at the posttranslational
level during assembly and/or transport to the cell surface. In
this respect, hIL-10 exposure to primary human monocytes
has been reported to induce expression of the membrane-
associated RING-CH (MARCH) ubiquitin ligase MARCH1,
which in turn acts as a posttranslational inhibitor of MHC class
II expression (98). It is therefore possible that any posttrans-
lational control of MHC class II by cmvIL-10 and/or LAcm-
vIL-10 could be manifested via upregulation of MARCH1, and
this is an area that warrants further investigation.
Although both LAcmvIL-10 and cmvIL-10 downmodulate
MHC class II on myeloid lineage cells, LAcmvIL-10 does not
appear to share the full repertoire of immunmodulatory func-
tions encoded by cmvIL-10. The immunosuppressive effects of
cmvIL-10 on DC maturation (8, 80) were not replicated by
LAcmvIL-10 on monocyte-derived DC stimulated with LPS
(44). Furthermore, unlike cmvIL-10 and hIL-10, LAcmvIL-10
was unable to stimulate the proliferation of the Daudi B cell
line (93), nor was it able to enhance Fc receptor-mediated
phagocytosis by human monocytes (40). These findings dem-
onstrate that LAcmvIL-10 retains only a small subset of the
biological properties of cmvIL-10 (and hIL-10).
Whether cmvIL-10 is expressed during latency remains to be
determined, but transcripts predicted to encode LAcmvIL-10
are expressed during productive infection of human fibroblasts
(43). The functional contribution of LAcmvIL-10 during pro-
ductive infection in unclear, but expression of latency-associ-
ated viral transcripts during both latent and productive phases
of infection has been reported for other HCMV transcripts,
including the major immediate-early region latent transcripts
(CLTs) and transcripts from the UL138 gene (29, 62), as well
as latency-associated transcripts expressed by other herpesvi-
ruses, herpes simplex virus type 1, varicella-zoster virus, EBV,
and pseudorabies virus (11, 14, 46, 56, 91, 95, 106, 107).
Clues to the mechanistic basis for the differences in func-
tions encoded by LAcmvIL-10 and cmvIL-10 can be found
by analysis of their receptor usage. cmvIL-10 functions by
binding and signaling through the hIL-10R (44, 54, 94). This
function is highlighted by the induction of phosphorylation
of Stat3, which is a well-documented signaling outcome fol-
lowing binding of hIL-10 or cmvIL-10 to the hIL-10R (20,
21, 53, 83, 92), as well as by the capacity to block immuno-
suppressive functions of cmvIL-10 by pretreating monocytes
with neutralizing antibodies to hIL-10R (44, 94). In contrast,
treatment of monocytes with LAcmvIL-10 does not induce
Stat3 phosphorylation, and LAcmvIL-10 retains the capacity
to downregulate MHC class II in the presence of hIL-10R-
neutralizing antibodies (44, 94). Thus, either LAcmvIL-10
binds and signals through a different, as yet unidentified
receptor, or it still binds to the hIL-10R but does so in a
manner which differs from that of cmvIL-10 and hIL-10.
Jones et al. (47) resolved the crystal structure of cmvIL-10
bound to hIL-10R1 and identified several regions in
cmvIL-10 important for binding to the hIL-10R. It was shown
that that cmvIL-10 uses essentially the same structural epitope as
that described for hIL-10, with helix A, the AB loop, and helix F
contacting IL-10R1. In the case of LAcmvIL-10, the absence of
amino acid residues coded by exon 3 of the UL111A transcript
results in the loss of the C-terminal helices E/F, which are present
in cmvIL-10. It has therefore been postulated that the truncation
in LAcmvIL-10 may result in a diminished capacity for
LAcmvIL-10 to dimerize or signal through the IL-10R complex,
accounting for the observed differences in the repertoire of im-
munomodulatory functions encoded by LAcmvIL-10 and
cmvIL-10 (44).
In addition to functional studies utilizing recombinant
vIL-10 proteins, it has recently been reported that the HCMV
UL111A gene can function to modulate immune function in
the context of latent infection of primary myeloid progenitor
cells (10a). Utilizing a UL111A delection virus which cannot
express any vIL-10, the authors showed that in both allogeneic
and autologous settings, CD4 T-cell recognition of latently
infected myeloid progenitors was regulated by this viral gene
and that this was likely a consequence of vIL 10-mediated
suppression of the capacity of latently infected cells to present
antigenic peptides via MHC class II. This study provides the
first evidence that a vIL-10 protein(s) expressed during latency
from the UL111A gene can render latently infected cells re-
fractory to CD4 T-cell recognition, implicating this viral gene
in maintenance of latency in the immunocompetent human
host.
ADDITIONAL HCMV IL-10 ISOFORMS
In addition to cmvIL-10 and LAcmvIL-10 transcripts, five
other, less-abundant vIL-10-like RNAs have been reported
during productive HCMV infection of MRC-5 fibroblast cells
(58). In this study, the start and stop sites of transcription were
not defined, and cDNA was amplified from the position of the
methionine used to initiate cmvIL-10 and LAcmvIL-10 trans-
lation at nucleotide position 159678, but based on alternate
splicing patterns these transcripts were predicted to encode
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novel vIL-10 homologs. Proteins expressed from cDNA con-
structs from these transcripts reacted with anti-cmvIL-10 anti-
body, and some evidence of protein expression of several of
these isoforms was detected in productively infected MRC-5
cells. None of the putative new isoforms were able to induce
Stat3 phosphorylation, but the authors contend that all vIL-10
isoforms are able to form heterodimers with hIL-10 and that at
least in the case of cmvIL-10, interaction with hIL-10 may
enhance the capacity of hIL-10 to induce Stat3 phosphoryla-
tion. Additional experiments will be required to strengthen
these conclusions, and it remains to be determined whether
these smaller products were not a consequence of the degra-
dation of the full-length cmvIL-10 protein, but this study points
to there being greater complexity in expression from the
UL111A gene region during productive infection.
vIL-10 HOMOLOGS ENCODED BY
NONHUMAN VIRUSES
Although a number of nonhuman viruses have been identi-
fied as encoding IL-10 homologs (Table 1), the biological prop-
erties of most of them remain to be determined. This section
summarizes what is currently known about the functions of
those homologs that have been subjected to some degree of
functional characterization, namely, ORFV, OvHV2, and rhe-
sus CMV (RhCMV).
Recombinant ORFV vIL-10, which has been extensively
studied (24–26, 33, 38, 55, 66, 105), inhibits TNF- and IL-8
synthesis in activated ovine and murine macrophages and stim-
ulates ovine mast cell proliferation at a level of activity indis-
tinguishable from that of ovine IL-10. Since ORFV vIL-10 is
91% identical to ovine IL-10, comparable functional activity is
not unexpected. However, a similar phenotype is observed for
OvHV2 vIL-10, which retains only 41% amino acid identity to
that of its ovine IL-10. The vIL-10 of OvHV2 stimulates mast
cell proliferation and inhibits IL-8 production from LPS-acti-
vated macrophages (41). As in other studies, there is nothing
that separates the phenotype of OvHV2 vIL-10 from that of
ovine IL-10. The importance of these functions to the natural
histories of ORFV and OvHV2 has been demonstrated by
analysis of engineered viral variants in which the vIL-10 gene
has been deleted.
The ORFV vIL-10 gene was disrupted and partially deleted
by engineering a lacZ cassette into the vIL-10 coding region
within the viral genome (24). Recovered virus (vIL-10ko) was
used to inoculate naïve sheep by scarification in parallel with
groups of sheep inoculated with either the parental unmodified
virus or “rescued” virus in which the fidelity of the vIL-10 gene
mutated with the lacZ cassette had been restored. In all cases,
the severity of the virus-induced lesions was reduced in the
vIL-10ko-inoculated sheep compared to that of both those
inoculated with the parental virus and those inoculated with
the “rescued” viruses. The severity of the lesions was reduced
over a range of inoculation titers (104 to 106 PFU), and statis-
tically significant reductions were observed at every time point
following inoculation with 105 and 106 PFU of virus. Statistical
significance was observed at a single time point following in-
oculation with 104 PFU, corresponding to the time of greatest
lesion severity in the animals inoculated with the wild type. The
loss of vIL-10 expression resulting from the lacZ insertion
resulted in a 100- to 1,000-fold reduction in lesion severity. The
authors of this study concluded that “the vorfIL-10 gene is
important in the establishment of infection by ORFV and that
innate responses (e.g., IFNs and TNF) could be important in
inhibiting ORFV replication during the early stages of infec-
tion.” This statement effectively captures what may be the most
salient aspect of vIL-10 functionality in the context of produc-
tive replication, namely, the manipulation of the earliest virus-
host interactions to enable an immune environment promoting
the successful completion of the virus’s infectious life cycle.
To date, RhCMV-encoded IL-10 has been subjected only to
limited published functional analysis. In a study of DNA vac-
cination of rhesus macaques, delivery of a construct expressing
RhCMV IL-10 did not alter the protective effects of DNA
vaccination with constructs expressing variants of two
RhCMV-immunogenic viral proteins, gB and pp65-2 (112).
The vIL-10 plasmid construct stimulated weak antibody and
cellular responses after three genetic immunizations. Notable
anamnestic responses were observed after challenge, demon-
strating that immunization with the vIL-10 plasmid primed
memory immune cells. RhCMV vIL-10 is immunogenic during
natural infection; vIL-10-specific T-cell responses are de-
tected in long-term-infected macaques, and degranulation
detected by flow cytometry reveals the phenotypic hetero-
geneity of degranulating CMV-specific CD8 T lymphocytes
in rhesus macaques (5).
DIVERGENCE AND CONSERVATION OF vIL-10 WITH
HOST IL-10
The progenitor Herpesviridae is estimated to have originated
200 to 240 million years ago (65), and it is generally thought
that descendent members coevolved with their hosts during
species radiation. Consistent with this, all but one (OvHV2) of
the vIL-10 proteins of the Gammaherpesvirinae retain high
sequence identity with the IL-10 protein of their respective
hosts (84 to 91%). In marked contrast, OvHV2 and the Beta-
herpesvirinae vIL-10 proteins are highly divergent from the
IL-10 protein of their host, retaining only 41% (OvHV2) and
25 to 29% amino acid identity, respectively (Table 1 and Fig. 2)
(41, 61). The vIL-10 ORFs of HCMV, RhCMV, ORFV, and
OvHV2 are not hypervariable regions among different isolates
of the viruses; independent isolates exhibit 98 to 100% se-
quence identity (26, 27, 41, 61). This indicates that the marked
sequence divergence between a vIL-10 and its host’s IL-10
probably occurred early during species radiation. Another way
to appreciate the extent of genetic drift is that the vIL-10
proteins of HCMV and RhCMV are as divergent from their
host’s IL-10 as they are from each other. The selective forces
driving this genetic drift and the reasons why it appears to be
limited to the Betaherpesvirinae are unknown. One potential
explanation that can be excluded is that divergence represents
compensatory genetic drift in the viral ligand as a result of
divergence in the cellular IL-10Rs. In fact, the high-affinity
IL-10Rs (IL-10R1) in humans and rhesus macaques (Ma-
caca mulatta) (GenBank accession numbers AAA17896 and
XP_001092736, respectively) are 90% identical. Moreover, if
compensatory drift was the mechanistic basis for the diver-
gence of the Betaherpesvirinae vIL-10 proteins, then it would be
expected that there would be comparable drift in the vIL-10-
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containing Gammaherpesvirinae infecting the same host. Both
EBV and macacine herpesvirus 4 are strongly conserved with
their IL-10 homologs (71, 84). It is noteworthy that within the
Cytomegalovirus genus of Betaherpesvirinae, the closest evolu-
tionary relative to HCMV, i.e., chimp CMV, does not encode
an IL-10 homolog (13). The vIL-10 gene is found in the same
genomic location in the monkey CMVs (macacine herpesvirus
3, African green monkey CMV, and baboon CMV) as in
HCMV. Therefore, the lack of vIL-10 in chimp CMV indicates
a deletion of this locus at some point after the split of the great
apes (Hominidae) and the Old World monkeys (Cercopitheci-
dae). The progenitors of fish and mammals split 400 million
years ago, and it is not surprising that the extent of amino acid
substitutions in the IL-10 proteins of the common carp and
mammals reflect this ancient evolutionary separation. The
vIL-10 of cyprinid herpesvirus 3 has undergone extensive di-
vergence relative to its host, suggesting that selective forces
similar to those acting on the Betaherpesvirinae may have been
at work for this fish herpesvirus. A comparable pattern of
genetic conservation and drift is apparent within the Poxviri-
dae; three closely-related viruses (SPPV, GPV, and LSDV)
express vIL-10 proteins highly divergent from their host’s IL-10
(38 to 45% sequence identity), while the vIL-10 of ORFV is
80% identical to ovine IL-10.
A more-likely explanation for the higher rate of amino acid
substitutions with particular vIL-10 proteins compared to that
with host IL-10 is that functional changes associated with
change in the protein sequence conferred some selective ad-
vantage over retention of the sequence of a transduced host
gene. The vIL-10 genes of HCMV and the monkey CMVs
consist of three and four exons, respectively, whereas the IL-10
gene is composed of five exons. Despite the loss of one and two
introns in the vIL-10 genes of monkey CMV and HCMV,
respectively, the remaining exon/exon boundaries are abso-
lutely conserved with those of IL-10. Similarly, the splicing
pattern of OvHV2 is identical to that of ovine IL-10 (five
exons). The splicing patterns are consistent with the interpre-
tation that the vIL-10 ORF represent the remnants of an
original transduced IL-10 gene. Accordingly, accumulation of
amino acid changes in the transduced IL-10 protein would
convert what was initially a “self” protein expressed from the
viral genome into more of a “nonself” protein. Since vIL-10 is
immunogenic in an infected host, presumably selective advan-
tages conferred by alteration in protein sequence exceeded the
costs associated with increased immune recognition by the
host. It is reasonable to predict that the divergence of vIL-10
proteins from host IL-10 was a positive selection for the alter-
ation of vIL-10 functionality, and this is supported by studies of
ebvIL-10 and the latency-associated homolog encoded by
HCMV (LAcmvIL-10), which demonstrate differences from
hIL-10 in the repertoire of biological functions and/or the
mechanism of action (28, 44, 59, 64, 93, 103). However, in vitro
assays have shown that the phenotype of full-length HCMV
IL-10 (cmvIL-10) mimics that of hIL-10 in terms of the func-
tional alterations to various cell types, signaling pathways, and
changes in gene expression (7, 8, 94), and the same is true for
the limited data available for other vIL-10 proteins.
CONCLUDING REMARKS
An important role of the potent immunomodulatory cyto-
kine IL-10 in virus infections has become increasingly clear in
recent years, and the acquisition of IL-10-like sequences by
viruses represents a remarkable evolutionary step which likely
equips the virus with a powerful tool to modulate host immune
function. A range of both human and nonhuman viruses have
been shown to encode IL-10 homologs, and the number will
undoubtedly grow as new sequence information becomes avail-
FIG. 2. Alignment of cellular and vIL-10 proteins. Proteins were aligned by the ClustalW method, using the MegAlign software program
(Lasergene, DNASTAR). Cellular and vIL-10 host names are shown in italic and bold fonts, respectively. Nucleotide sequence accession numbers
for the indicated genera or viruses are as follows: Ovis (sheep; GenBank accession number NP_001009327), Capra (goat; ABI20513), Bos (bovine;
NP_776513), ORFV (AAC57332), equine herpesvirus 2 ([EHV2] AAB26148), Equus (horse; NP_001075959), Papio (baboon; Q5Q0V6), Macaca
(rhesus macaque [Macaca mulatta]; NP_001038192), Homo sapiens (human; P22301), macacine herpesvirus 4 [McHV4]/rhesus lymphocryptovirus
(AAK95412), EBV/human herpesvirus 4 (P03180), OvHV2 (ABB22222), LSDV (AAN02729), SPPV (NP_659579), GPV (GPV Pellor;
YP_001293197), McHV3/RhCMV (AAF59907), African green monkey CMV ([AGMCMV] AAF63435), baboon CMV ([BaCMV] AAF63436),
HCMV/human herpesvirus 5 (AAF36285), Cyprinus (common carp [Cyprinus carpio]; BAC76885), cyprinid herpesvirus 3 ([CyHV3]
YP_001096169).
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able. Whether in acute, persistent, or latent infection settings,
the expression of virus-encoded homologs of IL-10 would serve
as an efficient means to interfere with multiple immune com-
ponents to ensure successful infection of the host. To date, all
of the virus-encoded IL-10 homologs tested have demon-
strated immunomodulatory properties, although these ho-
mologs do not always mimic the full range of properties en-
compassed by their cellular counterparts, nor by each other,
highlighting the complexity of this means of virus-encoded
immune control. While there is still much to be understood
about the full extent of the direct and indirect impacts of
vIL-10 on the host immune response to virus infections, their
discovery and the functional studies performed so far provide
a fascinating insight into the capacity of some viruses to ac-
quire a potent weapon with the potential to significantly influ-
ence the course of infection.
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